10/14/2009 | CVSS | Cell Genesys, BioSante complete merger; BioSante assumes obligations for 3.125% convertibles
|
7/13/2009 | SS | Kopp Investment Advisors reduces stake in Cell Genesys to 10.7%
|
6/23/2009 | CVDD | Cell Genesys to buy back most 3.125% convertibles, considers options
|
6/23/2009 | SS | Cell Genesys explores alternatives, including possible liquidation
|
5/22/2009 | CVDD | Cell Genesys starts exchange for $68.3 million convertible notes
|
5/11/2009 | CV | Cell Genesys will offer to exchange its 3.125% convertibles for new 3.125% convertibles
|
4/27/2009 | SS | Cell Genesys investor Kopp reports 12.69% ownership interest
|
4/9/2009 | PP | Cell Genesys terminates $75 million committed equity financing facility
|
3/9/2009 | CV | Cell Genesys buys back $74.1 million 3.125% convertibles at 60% discount
|
12/17/2008 | CV | Cell Genesys gets tenders for $47.8 million 3.125% convertibles
|
12/2/2008 | CV | Cell Genesys extends Dutch auction tender offer for 3.125% convertibles, ups minimum price
|
11/21/2008 | SS | Kopp keeps 6.35% interest in Cell Genesys
|
11/7/2008 | CV | Cell Genesys starts Dutch auction tender for $80 million 3.125% convertibles
|
10/24/2008 | CV | Cell Genesys buys back $26.3 million 3.125% convertibles at discount
|
8/27/2008 | CV | Market Commentary: Amylin, Cell Genesys fall on product bombshells; Bristol-Myers stands pat; Fannie Mae extends gains
|
5/12/2008 | PP | New Issue: Cell Genesys orchestrates $30 million direct offering of shares
|
5/12/2008 | PP | Market Commentary: GeoVax, Osisko get financing facilities; Cell Genesys, Oilsands sell stock; pipeline growing, Rodman says
|
4/25/2008 | SS | Kopp keeps 5.01% interest in Cell Genesys
|
2/15/2008 | CV | Market Commentary: Arris hounded by earnings, guidance; Priceline goes other way; Test results boost Cell Genesys
|
11/5/2007 | CV | Market Commentary: American Financial rallies on merger; Ford drives on labor deal; Royal Gold a shiny nugget
|
5/1/2007 | CV | Cell Genesys files $150 million shelf registration
|
4/13/2007 | PP | Market Commentary: Novelos Therapeutics secures $15 million from preferreds; EnerJex closes $9 million PIPE
|
4/12/2007 | PP | Market Commentary: Cell Therapeutics secures $37.2 million from PIPE; American Oil to raise $28.5 million in stock sale
|
4/11/2007 | PP | New Issue: Cell Genesys secures $60 million from direct placement of stock
|
4/11/2007 | PP | Market Commentary: Cell Genesys to close $60 million direct stock sale; Red Rock grabs $20 million equity line
|
4/10/2007 | CV | Market Commentary: Cell Genesys drops on drug speculation; Seagate falls on warning; General Growth, TriZetto launch deals
|
4/3/2007 | CV | Market Commentary: Cell Genesys soars on drug data; Continental gains outright; Digital Realty, Chattem, Borders launch deals
|
3/30/2007 | CV | Market Commentary: Cell Genesys climbs on drug hopes; Eddie Bauer, St. Mary lead new deals; RF Micro, Strategic Hotels trail
|
2/6/2007 | PP | Market Commentary: MFRI pockets $20.165 million from direct stock deal; ECO2 Plastics raises $13 million
|
2/5/2007 | PP | New Issue: Cell Genesys obtains $75 million equity line
|
2/5/2007 | PP | Market Commentary: Cell Genesys grabs $75 million equity line; Enzo secures $15 million from stock offering
|
9/8/2006 | BT | New Issue: Cell Genesys raises $25.3 million in follow-on of 5.75 million shares at $4.40 each
|
9/8/2006 | BT | Market Commentary: Discovery Labs spikes on buyout buzz; Cell Genesys loses 5% on bought deal; Oscient buffeted
|
9/8/2006 | CV | Market Commentary: National Retail gains on debut; Cell Genesys takes comfort in stock sale; AirTran dives on lowered outlook
|
9/7/2006 | BT | Cell Genesys plans follow-on sale of 5.75 million shares via Credit Suisse
|
9/7/2006 | BT | Market Commentary: New River falls over 10%; Cell Genesys loses 5% after-hours; Ligand, King up; Sinovac up 7%
|
7/18/2006 | BT | Cell Genesys expands enrollment of phase 1 trial of CG0070 for treatment of bladder cancer
|
7/12/2006 | BT | Market Commentary: Genzyme, Genentech 2Q results counteract; Curis retraces losses; Antigenics, CV, Cell Genesys up
|
7/5/2006 | BT | Cell Genesys: Results promising for GVAX immunotherapy to treat early prostate cancer
|
6/5/2006 | BT | Cell Genesys says addition of GVAX therapy lowers leukemia rate
|
5/22/2006 | BT | Cell Genesys bladder cancer trial shows antitumor activity in 33% of patients
|
5/10/2006 | CV | Market Commentary: SanDisk, Broadwing climb on debuts; Amkor, JDS Uniphase, Manor Care plan deals; Teva steady on loss
|
5/10/2006 | BT | Cell Genesys given fast track status for GVAX
|
4/3/2006 | BT | Market Commentary: Epix up 21% on Predix buy; Incyte falls 41%; Medarex off; Inhibitex plunges 66%; StemCells dives
|
3/29/2006 | BT | Market Commentary: Amylin shares up ahead of deal; Idenix off despite Novartis aid; Antigenics, cancer names higher
|
3/15/2006 | PP | Market Commentary: Cell Genesys stock settles off on $75 million equity line; GenVec inks $30 million equity line
|
3/15/2006 | BTPP | New Issue: Cell Genesys receives $75 million equity line
|
3/15/2006 | BT | Market Commentary: Cell Genesys rises then ends off; Critical Therapeutics loses 2%; Siga up 10%; Corautus rebounds
|
2/27/2006 | BT | Cell Genesys reports encouraging survival data from second phase 2 trial of GVAX
|
12/15/2005 | BT | Market Commentary: OSI Pharma on deck; Oxigene off on steep discount; BioCryst slips on PIPE; Somaxon sinks on debut
|
12/15/2005 | CV | Market Commentary: ON Semi, OSI Pharma at bat; Entergy goes to 50.5 bid; Intel steady; Abgenix issues climb
|
12/12/2005 | BT | Cell Genesys says GVAX phase 2 trial for leukemia shows positive results
|
11/22/2005 | BT | Cell Genesys sells San Diego manufacturing operation to Genzyme
|
11/15/2005 | BT | Market Commentary: Allergan bid a wrinkle in Medicis merger with Inamed; Biovail off on spinoff plan; SkyePharma up
|
11/15/2005 | BT | Cell Genesys reports favorable survival rates after two years from pancreatic cancer trial of GVAX
|
10/18/2005 | BT | Market Commentary: Amgen up; Abgenix, Cell Genesys lower; Chiron drops; Gilead sold on nice quarter; Genzyme seesaws
|
9/12/2005 | BT | Geron joins Myogen for Thursday; Cell Genesys up on back of Geron; OSI Pharma plummets on Tarceva
|
7/12/2005 | BT | Market Commentary: Planet Biotech targets VC funds; Rigel, Keryx decline; Genentech rises, pushes OSI Pharma higher
|
6/20/2005 | BT | Market Commentary: HemoSense cuts IPO range; Impax labs, Xoma gain on credit fronts; ImClone up on drug plans
|
5/11/2005 | CV | Market Commentary: Delta bankruptcy seen inevitable; GM, Ford weigh financials, IPG; KV Pharma slammed; Red Hat up
|
11/17/2004 | CV | Cell Genesys greenshoe exercised, raising convertibles to $145 million
|
10/18/2004 | CV | Market Commentary: Sirius convertibles up on Ford news; Elan active, edges up on Biogen buzz; CNet gains
|
10/15/2004 | CV | Market Commentary: Shoppers look for bargains among insurance rubble; Shanda up; Cell Genesys off
|
10/15/2004 | CV | New Issue: Cell Genesys upsized $110 million convertible at 3.125%, up 30%
|
10/14/2004 | CV | Market Commentary: Shanda, Cell Genesys bid up in gray market; insurers pulverized by Spitzer suit
|
10/12/2004 | BK | Cell Genesys to repay bank debt with convertible proceeds
|
10/12/2004 | CV | Cell Genesys $100 million convertible talked at 2.625%-3.125%, up 30%-35%
|
10/12/2004 | CV | Market Commentary: Apex Silver hovers around par; Amkor firms as bids hit; NPS Pharma, biotechs suffer
|